If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
187
results.
Updated on
19/04/2026 [06:51:00]
Results 100 to 125 of 187
Absstract of: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Absstract of: MX2025011256A
The present application is directed, in general, to compositions comprising tolerizing immune modifying particles encapsulating Myasthenia Gravis (MG) associated antigens, methods of treating MG using tolerizing immune modifying nanoparticles encapsulating MG associated antigens, and a process for the preparation of tolerizing immune modifying nanoparticles encapsulating MG antigens.
Absstract of: JP2026511197A
本発明は、少なくとも1つのゼオライトナノ結晶から成る、又は、少なくとも1つのゼオライトナノ結晶を含むナノ粒子を合成する方法であって、－アルミニウム供給源と、アルカリ金属Ｍ、とりわけＫのイオンの供給源とを含む、第一の組成物／溶液１が調製され；－ケイ素供給源と、アルカリ金属Ｍ、とりわけＫのイオンの供給源とを含む、第二の組成物／溶液２が調製され、ここで、前記組成物／溶液１及び２は、何らの有機構造化剤をも含まない；－前記２つの組成物／溶液１及び２が一緒に混合され；－前記混合物が結晶化され；かつ、－このようにして形成された前記ナノ粒子が分離されてよい方法に関する。本発明によれば、前記第一の組成物／溶液１及び前記第二の組成物／溶液２はいずれも、前記供給源及びリン酸緩衝生理食塩水から成る。本発明はまた、得られたナノ粒子のコロイド状懸濁液及び該ナノ粒子を含む医薬品組成物に関する。
Absstract of: CN120826370A
The invention relates to a method for synthesizing nanoparticles consisting of or comprising at least one zeolite nanocrystal, comprising:-preparing a first composition/solution 1 comprising a source of aluminum and a source of ions of an alkali metal M, in particular of Na; preparing a second composition/solution 2 containing a source of silicon and a source of ions of an alkali metal M, in particular of Na, said compositions/solutions 1 and 2 being free of any organic structure directing agent; -mixing compositions/solutions 1 and 2 and placing the mixture under stirring; crystallizing the mixture at a temperature greater than or equal to 50 DEG C; and-optionally separating the formed nanoparticles. According to the invention, the first composition/solution 1 and the second composition/solution 2 each consist of said source and an alkaline phosphate buffer (PBS). The invention also relates to the nanoparticles thus obtained and to compositions containing these nanoparticles.
Absstract of: WO2024206076A1
The present disclosure pertains to biodegradable polymeric microspheres that comprise a biodegradable polymer and an immunotherapeutic agent selected from an inhibitor of poly ADP ribose polymerase enzyme (PARP inhibitor) and/or a Toll-like receptor (TLR) agonist wherein (a) 50% of a total amount of the immunotherapeutic agent in the biodegradable polymeric microspheres is released from the biodegradable polymeric microspheres into a 37°C solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; (b) between 1 mg and 100 mg of immunotherapeutic agent per 1 g dry weight of microspheres is released from the biodegradable polymeric microspheres into a 37°C solution of PBS Tween 20 (0.05%) at a point in time ranging from 3 days and 14 days; or (c) both (a) and (b). Other aspects of the present disclosure pertain to methods of using such microparticles and kits that contain such microparticles.
Absstract of: JP2026511099A
本明細書では、ＬＰＡ遺伝子におけるインビボ編集を達成することを対象とする遺伝子編集システム及び組成物が提供される。遺伝子編集によるアポ（ａ）産生の妨害及び血中リポタンパク質（ａ）［Ｌｐ（ａ）］濃度の低減による心血管疾患の治療又は予防が本明細書に開示される。ＬＰＡのコード配列における挿入及び／又は欠失（インデルバリアント）及び／又は非同義バリアントの導入を達成するように設計されたニッカーゼに基づく遺伝子編集システムが開示される。ニッカーゼに基づく遺伝子編集システムは一般に、１つ以上のニッカーゼと、複数のガイドオリゴヌクレオチド（例えば、ｇＲＮＡ）をコードする１つ以上のｍＲＮＡとを含み、それを必要とする哺乳動物対象に、潜在的に一回限りの治療として、（ＧａｌＮＡｃ標的化部分を有する、又は有さない）脂質ナノ粒子（ＬＮＰ）などの好適な送達システムを介して静脈内にインビボで送達され得るか、又は別の方法で投与され得る。遺伝子編集システム及び組成物の製造、使用、及び製剤化も開示される。
Absstract of: WO2024193827A1
The present disclosure relates generally to the field of stabilized compositions comprising particles dispersed in an aqueous phase, wherein the aqueous phase comprises a buffer system and has a pH of about 4.0-5.5 and wherein the particles contain (i) nucleic acid (such as DNA or RNA, in particular mRNA or inhibitory RNA, e.g., siRNA); and (ii) a cationic or cationically ionizable lipid, methods for preparing and storing such compositions, and the use of such compositions in therapy.
Absstract of: WO2021226108A1
Disclosed are pharmaceutical or cosmetic compositions comprising secretomes, for example secreted proteins from stem cells, and uses thereof. A composition that contains a secretome and an acceptable excipient may be free of a cell. The compositions are useful for inducing an immune response, treating an inflammatory response, treating a microbial infection, differentiating cells, wound healing, embryonic development, placental development, central nervous system development, or morphogenesis.
Absstract of: US20260096998A1
0000 The present disclosure provides complexes and methods of use. In some embodiments, a complex described herein is a complex comprising a cationic polymer, an anionic polymer, and a monomeric RNA molecule, wherein the cationic polymer and the monomeric RNA molecule form a core complex encapsulated by the anionic polymer. In some embodiments, a complex comprises a linear cationic polymer, an anionic polymer, and a monomeric RNA molecule, wherein the cationic polymer and the monomeric RNA molecule form a core complex encapsulated by the anionic polymer.
Absstract of: US20260098070A1
0000 Provided herein are fusion molecules comprising a SMAGP extracellular domain that can modulate leukocyte activity. Also provided are polynucleotides, vectors, and host cells encoding these fusion molecules, and methods of making and using these fusion molecules.
Absstract of: US20260097138A1
Metal based nanoparticles coated with a polymer functionalized with thiol groups and —NH groups are provided. The polymer can be thiolated chitosan, thiolated and aminated alginic acid, thiolated and aminated hyaluronic acid, or a protein such as albumin or gelatin, or a synthetic thiolated and aminated polymer such as α-thio-ω-amino polyethylene glycols. The groups are linked to a ligand of the integrin family receptors via a heterobifunctional crosslinker bearing functional groups able to bind to amino groups such as N-hydroxysuccinimidyl ester group (NHS ester), an isocyanate group (—NCO), an isothiocyanate group (—NCS), a Sulfo-N-hydroxysuccinimidyl ester group (sulfo-NHS ester), or a carboxylic acid group which is connected by activation with carbodiimide coupling agents; and/or a functional group able to bind thiol groups.
Absstract of: US20260097000A1
The present invention relates to a method of treatment wherein a composition comprising a cannabinoid and an amphiphilic carbohydrate compound such as GCPQ is administered intranasally. The method of treatment is particularly suitable for use in central nervous system disorders. The invention further relates to the composition when formulated with other components in pharmaceutical compositions for use in therapy.
Absstract of: WO2026076254A1
The disclosure relates to methods of using block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to methods of using polymer nanoparticles for delivering nucleic acids for treating NF1.
Absstract of: WO2026076268A1
The present invention relates to a system and method for generating and dispersing a mixture of nanoparticles and ions for neutralization of airborne pathogens in enclosed environments. A nebulizer introduces a salt precursor into a flame ionization stage, which produces a mixture of ions and nanoparticles at concentrations of at least 1.0 X 10^12 particles per cubic centimeter of air. The nanoparticles have an average size of less than 10 nanometers, and at approximately equal proportions with the ions. The systems and methods of the present invention reduce the pathogen viability by neutralization, inactivation, and agglomeration, and operate substantially free of ozone and, in alternate embodiments, include a two-duct alternating filtration arrangement for efficiency. Methods of testing include introducing pathogen surrogates into a chamber, generating the mixture of nanoparticles and ions by flame ionization, dispersing the mixture, and analyzing samples using aerosol and microbiological characterization techniques.
Absstract of: US20260096990A1
0000 A polymeric delivery system delivers a biologic to cells. In some embodiments, the polymeric delivery system includes polyplexes. Each polyplex includes at least one charged polymer and at least one biologic. The at least one charged polymer includes a polyester copolymer of a polyol and a polycarboxylic acid modified with at least one charged moiety having an opposite charge from a net charge of the at least one biologic. In other embodiments, the polymeric delivery system includes self-assembled particles including a block copolymer and a biologic associated with the block copolymer. The block copolymer includes a first block of a polyester copolymer of a polyol and a polycarboxylic acid and a second block of a second monomer or a second polymer.
Absstract of: US20260096988A1
0000 The present application provides liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides. The present application also provides nanodiamond complexes and particles as carriers for anti-cancer agents
Absstract of: US20260096997A1
0000 A composition for the controlled release of a nucleic acid such as short interfering RNA or messenger RNA, comprising silicon nanoparticles, at least one amino acid, and at least one lipid, wherein the silicon nanoparticles comprise at least 50% by weight silicon. Also related compositions and methods.
Absstract of: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Absstract of: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Absstract of: AU2026202230A1
Nucleic acid constructs that allow insertion and/or expression of a sequence of interest, such as a transgene, are provided. Compositions and methods of using such constructs for expression of a polypeptide or therapeutic agent, for example, are also provided. ar a r
Absstract of: AU2026202084A1
AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR Provided herein are methods that include introducing into an inner ear of a mammal a therapeutically effective amount of an adeno-associated virus (AAV) 5 vector that includes a nucleotide sequence encoding (a) a polypeptide including an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide including an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide including an antigen-binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor 10 receptor operably linked to a signal peptide. ar - a r
Absstract of: US20260096986A1
Drug delivery systems comprising a floating interpenetrating network (IPN) are provided. The pharmaceutical compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent, such that upon oral ingestion of the compositions, a floating IPN is formed in situ. These floating IPN provide extended release of the drug entrapped therein for at least about 3 hours.
Absstract of: WO2025072751A1
The disclosure relates to block copolymer nanoparticles for in vivo therapeutic delivery, and methods therefor. More particularly, the invention relates to polymer nanoparticles, such as reversible addition-fragmentation chain transfer (RAFT) polymer compositions, for delivering nucleotides that encode polypeptides.
Absstract of: US20260097001A1
0000 A nanoparticle having a solid core comprising a biologically active substance, said core being enclosed by an inorganic coating, a method for preparing the nanoparticle, and the use of the nanoparticle in therapy. A kit comprising the nanoparticle and a pharmaceutical composition comprising the nanoparticle.
Nº publicación: US20260097133A1 09/04/2026
Applicant:
EPIGENIC THERAPEUTICS PTE LTD [SG]
Absstract of: US20260097133A1
0000 The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.
BOPI
Electronic site
